FDA Approved: COMETRIQ — Original Application (Exelixis, Inc.)

View source ↗

Summary

The FDA approved Cometriq (cabozantinib) from Exelixis as the original application for the treatment of metastatic medullary thyroid carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• COMETRIQ (CABOZANTINIB)

Snippet

ORIG AP for COMETRIQ (CABOZANTINIB)